Company Filing History:
Years Active: 2008
Title: Franz-Georg Hanisch: Innovator in Tumor Vaccine Development
Introduction
Franz-Georg Hanisch is a notable inventor based in Kö'ln, Germany. He has made significant contributions to the field of medical research, particularly in the development of tumor vaccines. His work focuses on innovative solutions for combating MUC1-positive carcinomas, which are a type of cancer.
Latest Patents
Hanisch holds a patent for tumor vaccines specifically designed for MUC1-positive carcinomas. This patent presents a tumor vaccine that contains synthetic peptides comprising sequences of the human epithelial mucin MUC1. The vaccine includes the immunodominant region PDTRPAP, which is glycosylated at the threonine. The preferred glycosylation of this region is O-glycosidically linked to a-N-acetylgalactosamine (GalNAc) or short-chained oligosaccharides. This invention has the potential to be utilized in treating all MUC1-positive carcinomas.
Career Highlights
Franz-Georg Hanisch is associated with the Max-Delbrück-Centrum für Molekulare Medizin, where he continues to advance his research in molecular medicine. His work has garnered attention for its innovative approach to cancer treatment.
Collaborations
Hanisch collaborates with various professionals in his field, including his coworker Hans Paulsen. Their combined expertise contributes to the ongoing research and development of effective cancer therapies.
Conclusion
Franz-Georg Hanisch is a pioneering inventor whose work in tumor vaccines represents a significant advancement in cancer treatment. His innovative approaches and collaborations continue to inspire progress in the medical research community.